Studies recommending palivizumab restriction have serious deficiencies.
Stewart
Dan L
DL
D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000191:economics* / Q000627:therapeutic use; D015986:Confounding Factors, Epidemiologic; D017046:Cost Savings; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D000069455:Palivizumab; D012051:Reimbursement Mechanisms / Q000191:economics; D012106:Research / Q000592:standards*; D012107:Research Design; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy / Q000191:economics; D015983:Selection Bias
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab